California to sue Lilly, other drug companies over insulin prices
California on Thursday announced it will sue the companies that make and promote most of the nation’s insulin, accusing them of scheming to illegally increase the price of the drug.
Pharmaceutical
Articles
Alzheimer’s drug that modestly slows disease OK’d by FDA
It’s the first drug that’s been convincingly shown to slow the decline in memory and thinking that define the disease. But the medication comes with downsides, including potentially serious side effects and the need for frequent drug infusions.
With stock trading near record high, Lilly embarks on ambitious 2023
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
Indiana to receive $219M from CVS, Walgreens in opioid settlements
CVS and Walgreens have agreed to pay state and local governments a combined total of more than $10 billion to settle lawsuits over the toll of opioids.
Scathing report urges major changes at FDA, including possibly breaking up agency
The report comes in the wake of heavy criticism of the agency’s handling of a formula shortage earlier this year. Food safety experts have long complained that the agency’s food oversight arm has been chronically understaffed and underfunded.
Diabetes drug Lilly abandoned has new life
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
Opioid settlement cash to be in local hands within a week
Months after Indiana’s attorney general said he’d send about 660 local governments their shares of the state’s $507 million opioid crisis settlement with drug manufacturers and distributors, none have received the money.
Catalent laying off 400 employees in Bloomington
Since 2020, Catalent had been rapidly expanding operations as it produced vaccines for both Johnson & Johnson and Moderna Inc.
Inotiv plans to close two Indianapolis facilities in consolidation
The pharmaceutical testing company said it plans to close two isolator facilities in Indianapolis and consolidate them with existing facilities in the United States.
Drug slows Alzheimer’s, but can it make a real difference?
An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday—but it remains unclear whether that will have an impact on people’s lives.
Roche’s Alzheimer’s drug fails in fresh blow to fraught field
Gantenerumab’s demise is a boost for Indianapolis-based Eli Lilly and Biogen, which are also developing treatments for Alzheimer’s, said Tim Anderson, an analyst at Wolfe Research. Lilly shares were up 1.8% at midday.
MBX Biosciences closes on $115M in drug-development funding
The funding amount is one of the largest in recent years for an Indiana-based science startup.
Paxlovid may reduce long COVID risk for some patients, study finds
Even as vaccines have reduced the risk of hospitalization and death from infection with SARS-CoV-2, researchers continue to worry about the individual suffering and population-wide threats from long COVID.
Pfizer study says updated COVID boosters rev up protection
Pfizer said people 55 and older who got the omicron-targeting booster had four-fold higher antibody levels than those given an extra dose of the original vaccine.
U.S. agency softens opioid prescribing guidelines for doctors
The previous guidance succeeded in reducing inappropriate and dangerous prescribing, some experts say. But they also were seen as a barrier to care, with some pharmacists refusing to fill prescriptions as doctors wrote them.
CVS, Walgreens announce opioid settlements totaling $10B
The developments amount to what could be the last round of huge settlements after years of litigation over the drug industry’s role in an overdose crisis that has been linked to more than 500,000 U.S. deaths over the past two decades.
Lilly shares stumble on lower profit outlook despite solid quarter
Eli Lilly stock has skyrocketed 36% in the past 52 weeks due to strong sales on newer drugs, but the market reacted negatively to its latest forecast.
Lilly commits $92.5M to Purdue for drug research, scholarships
In a significant expansion of their longstanding collaboration, the partners hope to develop new models for delivering therapies to patients and provide full tuition to between 75 and 100 students each year for 10 years.
Australian biopharma firm begins work at new HQ in Fishers
Telix Americas is leasing 10,000 square feet at the Crew CarWash headquarters building at 11700 Exit Five Parkway, near Interstate 69 and East 116th Street.
Coronavirus variant swarm could fuel winter surge
Any variant that winds up dominating in coming months will probably challenge a key line of treatment and protection for people with compromised immune systems—the drugs known as monoclonal antibodies.